SHORT COMMUNICATION
Clonidine decreases kynurenic acid production in rat brain cortex in vitro – a novel antihypertensive mechanism of action?
 
More details
Hide details
1
Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Poland
CORRESPONDING AUTHOR
Izabela Zakrocka   

Collegium Pathologicum, Department of Experimental and Clinical Pharmacology, Jaczewskiego 8, 20-090 Lublin, Poland
 
J Pre Clin Clin Res. 2016;10(1):57–59
KEYWORDS
ABSTRACT
Introduction:
Clonidine, an antihypertensive agent, is known to activate presynaptic α2-adrenoreceptors and imidazoline receptors in the central nervous system. Clonidine may also have influence on glutamatergic neurotransmission. Kynurenic acid (KYNA) is an endogenous antagonist of excitatory amino acid receptors. Cerebral KYNA synthesis from its bioprecursor L-kynurenine is regulated by aminotransferases localized preferentially within astrocytes. KYNA was shown to display potent neuroprotective properties. Moreover, it was reported that KYNA could reduce blood pressure levels in animal model of hypertension. The aim of the study was to discover whether the central antihypertensive agent clonidine has an influence on kynurenic acid (KYNA) production in rat brain cortex in vitro.

Material and Methods:
Cortical slices and brain cortical homogenates were incubated for 2 hours in the presence of KYNA precursor – L-kynurenine and clonidine. KYNA was separated chromatographically and detected fluorometrically.

Results:
Clonidine at the concentration of 0.001 mM – 0.1 mM did not affect KYNA production in rat brain cortex in vitro. It decreased KYNA production in rat brain cortical slices at concentrations 0.5–5 mM. Clonidine at all tested concentrations influenced neither KAT I nor KAT II activity

Conclusions:
The study revealed that clonidine decreases KYNA production in rat brain cortex in vitro. The obtained results suggest that augmentation of glutamatergic transmission may play an important role in the antihypertensive action of clonidine.

 
REFERENCES (24)
1.
Isaac L. Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol. 1980; 2: S5–19.
 
2.
Kuz’min AI, Lodygin DN, Kalenikova EI, Bychkova EIu, Khokhlova ON, Murashev AN et al. Pharmacological analysis of the role of central alpha-2 adrenergic and imidazoline receptors in mechanism of the hypotensive effect of clonidine in rats. Eksp Klin Farmakol. 2000; 63: 24–8.
 
3.
Tingley FD 3rd, Arnerić SP. Evidence for clonidine presynaptically modulating amino acid release in the rostral ventral medulla: role in hypertension. Brain Res. 1990; 537: 175–81.
 
4.
Reis DJ. Neurons and receptors in the rostroventrolateral medulla mediating the antihypertensive actions of drugs acting at imidazoline receptors. J Cardiovasc Pharmacol. 1996; 27: S11–18.
 
5.
Sved AF, Ito S, Yajima Y. Role of excitatory amino acid inputs to the rostral ventrolateral medulla in cardiovascular regulation. Clin Exp Pharmacol Physiol. 2002; 29: 503–6.
 
6.
Bergamaschi C, Campos RR, Schor N, Lopes OU. Role of the rostral ventrolateral medulla in maintenance of blood pressure in rats with Goldblatt hypertension. Hypertension. 1995; 26: 1117–20.
 
7.
Wang LG, Zeng J, Yuan WJ, Su DF, Wang WZ. Comparative study of NMDA and AMPA/kainate receptors involved in cardiovascular inhibition produced by imidazoline-like drugs in anaesthetized rats. Exp Physiol. 2007; 92: 849–58.
 
8.
Wang WZ, Wang LG, Gao L, Wang W. Contribution of AMPA/kainate receptors in the rostral ventrolateral medulla to the hypotensive and sympathoinhibitory effects of clonidine. Am J Physiol Regul Integr Comp Physiol. 2007; 293: R1232–8.
 
9.
Wang WZ, Yuan WJ, Su DF. Blockade of N-methyl-D-aspartate receptors within the rostral ventrolateral medulla antagonizes clonidine-induced cardiovascular effects. Auton Neurosci. 2003; 109: 21–8.
 
10.
Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001; 21: 7463–73.
 
11.
Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther. 2002; 303: 1–10.
 
12.
Ito S, Komatsu K, Tsukamoto K, Sved AF. Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats. Hypertension. 2000; 35: 413–7.
 
13.
Araujo GC, Lopes OU, Campos RR. Importance of glycinergic and glutamatergic synapses within the rostral ventrolateral medulla for blood pressure regulation in conscious rats. Hypertension. 1999; 34: 752–5.
 
14.
Mills E, Minson J, Drolet G, Chalmers J. Effect of intrathecal amino acid receptor antagonists on basal blood pressure and pressor responses to brainstem stimulation in normotensive and hypertensive rats. J Cardiovasc Pharmacol. 1990; 15: 877–83.
 
15.
Turski WA, Gramsbergen JB, Traitler H, Schwarcz R. Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. J Neurochem. 1989; 52: 1629–36.
 
16.
Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991; 56: 2007–17.
 
17.
Kamisaki Y, Hamada T, Maeda K, Ishimura M, Itoh T. Presynaptic alpha 2 adrenoceptors inhibit glutamate release from rat spinal cord synaptosomes. J Neurochem. 1993; 60: 522–6.
 
18.
Meana JJ, Herrera-Marschitz M, Goiny M. In vivo modulation of norepinephrine and glutamate release through imidazoline receptors in the rat central nervous system. Ann N Y Acad Sci. 1995; 763: 490–3.
 
19.
Bickler PE, Hansen BM. Alpha 2-adrenergic agonists reduce glutamate release and glutamate receptor-mediated calcium changes in hippocampal slices during hypoxia. Neuropharmacology. 1996; 35: 679–87.
 
20.
Shinomura T, Nakao S, Adachi T, Shingu K. Clonidine inhibits and phorbol acetate activates glutamate release from rat spinal synaptoneurosomes. Anesth Analg. 1999; 88: 1401–5.
 
21.
Urbańska EM, Chmielewski M, Kocki T, Turski WA. Formation of endogenous glutamatergic receptors antagonist kynurenic acid-differences between cortical and spinal cord slices. Brain Res. 2000; 878: 210–2.
 
22.
Milhaud D, Fagni L, Bockaert J, Lafon-Cazal M. Imidazoline-induced neuroprotective effects result from blockade of NMDA receptor channels in neuronal cultures. Neuropharmacology. 2000; 39: 2244–54.
 
23.
Olmos G, Ribera J, García-Sevilla JA. Imidazoli(di)ne compounds interact with the phencyclidine site of NMDA receptors in the rat brain. Eur J Pharmacol. 1996; 310: 273–6.
 
24.
Olmos G, DeGregorio-Rocasolano N, Paz Regalado M, Gasull T, Assumpció Boronat M, Trullas R et al. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol. 1997; 127: 1317–26.
 
eISSN:1898-7516
ISSN:1898-2395